CD4 and myeloid sarcoma: In both HD and MS patients, within CD4+CD25+CD127loTreg gate, the highest expression of CXCR3 was in Population II (50.49±2.28%) compared to Population I (12.63±1.72%, p < 0.0001) and Population III (33.8±1.73%, p < 0.0001) (Fig. 5C).